Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endo Health Solutions Inc Lowers FY 2013 Guidance-DJ


Wednesday, 5 Jun 2013 04:51pm EDT 

Dow Jones reported that Endo Health Solutions Inc cut its fiscal 2013 guidance and now expects adjusted earnings of $4.10 to $4.40 a share (EPS) and revenue of $2.65 billion to $2.8 billion. Its prior view called for earnings of $4.40 to $4.70 a share (EPS) and revenue of $2.8 billion to $2.95 billion. The revised guidance reflects the Company's new cost-cutting initiatives as well as the U.S. Food and Drug Administration's recent denial of a petition that would have halted generic competition to Endo's Opana painkiller. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $2.8 billion and EPS of $4.27 for fiscal 2013. 

Latest Key Developments in Pharmaceuticals

Company Quote

65.74
-0.56 -0.84%
11 Jul 2014